Shearman & Sterling represented UBS AG, BNP Paribas (Suisse) SA and Credit Suisse AG in connection with Amgen Inc.’s Regulation S offering of CHF 700 million aggregate principal amount of 0.410% notes due 2023. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The Team